Ergotamines work by acting as nonselective serotonin receptor agonists, producing vasoconstriction of cranial and other blood vessels. They stimulate multiple serotonin receptors, not just one subtype, with a prominent effect on receptors involved in vascular tone. This constriction reduces the pulsatile dilation and neurogenic inflammation thought to contribute to migraine symptoms, providing relief. Because they’re not highly selective, ergotamines also interact with other receptor systems (such as alpha-adrenergic and dopaminergic receptors), which helps explain their potent vasoconstrictive effects and broader side effects. This distinguishes them from drugs that are designed to be selective 5-HT1B/1D receptor agonists, like the triptans, which target a specific receptor subset to relieve migraine. In short, ergotamines are nonspecific serotonin receptor agonists with vasoconstrictive effects, rather than a dopamine antagonist, a CGRP receptor antagonist, or a strictly selective 5-HT1B/1D receptor agonist.

When using onabotulinumtoxin A for chronic migraine prevention, the side effects most often come from the local effect on nearby muscles where the injections are given. Injecting into pericranial and neck muscles can cause muscle soreness and temporary changes in muscle tone, so neck pain and headache are commonly reported after treatment. In contrast, severe hepatotoxicity, tremor with weight gain, or seizures are not typical adverse effects of this localized therapy. Therefore, neck pain and headache best describe a common adverse effect.

The main idea is that CGRP monoclonal antibodies are given by subcutaneous injections at regular intervals, not daily pills or weekly infusions. Most of these agents are dosed monthly by subcutaneous injection, with fremanezumab offering either monthly or quarterly schedules depending on the regimen. An important exception is eptinezumab, which is given by intravenous infusion every 12 weeks. So the typical prescription pattern is subcutaneous injections at monthly or quarterly intervals, depending on the specific agent.

The risk being tested is the potential for dangerous vasospasm from combining two drugs that both constrict blood vessels through serotonin receptor activity. Triptans activate 5-HT1B/1D receptors on cranial vessels, causing vasoconstriction and reducing CGRP-mediated pain signaling. Ergot derivatives are nonspecific serotonergic agents (and also interact with other receptors) that produce strong vasoconstriction. When used together, their effects can sum to excessive constriction of cerebral and peripheral arteries, increasing the chance of ischemia or infarction in the brain, heart, or extremities. That’s why this combination is contraindicated. It isn’t a matter of safety in pregnancy, nor does it reduce efficacy of triptans; there is a real added risk of vasospasm.